Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients
1 other identifier
observational
11
1 country
2
Brief Summary
Liver dysfunction marked by elevated alanine transaminase enzymes is quite common in dengue patients and subsequently affects the disease's severity and healing process. Unfortunately, liver function tests cannot always be done, especially in hospitals with limited facilities. In contrast, routine hematology tests are considered regular and inexpensive tests that can be performed on dengue patients. Therefore, this study aims to determine hematological parameters as markers of elevated liver enzymes in dengue patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2022
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2022
CompletedStudy Start
First participant enrolled
June 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 3, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 5, 2022
CompletedFirst Posted
Study publicly available on registry
June 7, 2022
CompletedJune 7, 2022
June 1, 2022
Same day
June 1, 2022
June 1, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Correlation of SGPT/ALT with Lymphocytes
Correlation of SGPT/ALT with Lymphocytes
May 30-June 5 2022
Correlation of SGPT/ALT with HFLC
Correlation of SGPT/ALT with HFLC
May 30-June 5 2022
Interventions
Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
Eligibility Criteria
This study is a cross-sectional study involving 11 dengue fever patients, consisting of 9 men and 2 women at Sebelas Maret University Hospital (RS UNS), Sukoharjo.
You may qualify if:
- patients who were hospitalized at UNS Hospital with the following criteria: (1) adult patients (19-65 years); (2) diagnosed with dengue hemorrhagic fever according to WHO 2011 criteria; (3) routine blood examination at least once in seven days since the onset of fever; and (4) checked alanine transaminase and aspartate transaminase levels at least once in seven days from the onset of fever.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
RS UNS (Universitas Sebelas Maret Hospital)
Sukoharjo, Central Java, 57161, Indonesia
Universitas Sebelas Maret Hospital
Sukoharjo, Central Java, 57161, Indonesia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nurhasan Agung Prabowo, MD
Universitas Sebelas Maret
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- dr. Nurhasan Agung Prabowo, Sp.PD
Study Record Dates
First Submitted
June 1, 2022
First Posted
June 7, 2022
Study Start
June 3, 2022
Primary Completion
June 3, 2022
Study Completion
June 5, 2022
Last Updated
June 7, 2022
Record last verified: 2022-06
Data Sharing
- IPD Sharing
- Will not share